Mori S, Inaniwa T, Miki K, Tanimoto K, Tajiri M, Kuroiwa D, Nakao M, Shiraishi Y, Shibayama K, Tsuji H
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Br J Radiol. 2015 Jul;88(1051):20140623. doi: 10.1259/bjr.20140623. Epub 2015 May 7.
We assessed the impact of changes in patient position on carbon-ion scanning beam distribution during treatment for prostate cancer.
68 patients were selected. Carbon-ion scanning dose was calculated. Two different planning target volumes (PTVs) were defined: PTV1 was the clinical target volume plus a set-up margin for the anterior/lateral sides and posterior side, while PTV2 was the same as PTV1 minus the posterior side. Total prescribed doses of 34.4 Gy [relative biological effectiveness (RBE)] and 17.2 Gy (RBE) were given to PTV1 and PTV2, respectively. To estimate the influence of geometric variations on dose distribution, the dose was recalculated on the rigidly shifted single planning CT based on two dimensional-three dimensional rigid registration of the orthogonal radiographs before and after treatment for the fraction of maximum positional changes.
Intrafractional patient positional change values averaged over all patients throughout the treatment course were less than the target registration error = 2.00 mm and angular error = 1.27°. However, these maximum positional errors did not occur in all 12 treatment fractions. Even though large positional changes occurred during irradiation in all treatment fractions, lowest dose encompassing 95% of the target (D95)-PTV1 was >98% of the prescribed dose.
Intrafractional patient positional changes occurred during treatment beam irradiation and degraded carbon-ion beam dose distribution. Our evaluation did not consider non-rigid deformations, however, dose distribution was still within clinically acceptable levels.
Inter- and intrafractional changes did not affect carbon-ion beam prostate treatment accuracy.
我们评估了前列腺癌治疗过程中患者体位变化对碳离子扫描束分布的影响。
选取68例患者。计算碳离子扫描剂量。定义了两个不同的计划靶区(PTV):PTV1为临床靶区加上前/外侧和后侧的摆位边界,而PTV2与PTV1相同,但减去后侧。分别给予PTV1和PTV2 34.4 Gy[相对生物效应(RBE)]和17.2 Gy(RBE)的总处方剂量。为了估计几何变化对剂量分布的影响,基于治疗前后正交射线照片的二维-三维刚性配准,在刚性移位的单次计划CT上重新计算最大位置变化部分的剂量。
在整个治疗过程中,所有患者的分次内患者体位变化值平均小于靶区配准误差=2.00 mm和角度误差=1.27°。然而,这些最大位置误差并非在所有12个治疗分次中都出现。尽管在所有治疗分次的照射过程中都发生了较大的位置变化,但包含95%靶区的最低剂量(D95)-PTV1仍>处方剂量的98%。
在治疗束照射过程中发生了分次内患者体位变化,这会使碳离子束剂量分布变差。我们的评估未考虑非刚性变形,然而,剂量分布仍在临床可接受水平内。
分次间和分次内的变化并未影响碳离子束前列腺治疗的准确性。